Glenmark Pharmaceuticals Ltd.
Snapshot View

View in App

Prices View details >>

435.10 -9.90 ▼-2.2%

21 March 2023, 04:01:00 PM
Volume: 60,166

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.glenmarkpharma.com
Market Cap 12,398.47 Cr.
Enterprise Value(EV) 15,270.50 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 31.23 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 14.07 Trailing Twelve Months Ending 2022-12
Industry PE 31.71 Trailing Twelve Months Ending 2022-12
Book Value / Share 349.11 Trailing Twelve Months Ending 2022-12
Price to Book Value 1.26 Calculated using Price: 439.40
Dividend Yield 0.57 Period Ending 2022-03
No. of Shares Subscribed 28.22 Cr. 282,168,156 Shares
FaceValue 1
Company Profile
The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark's ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark's formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-2.22%
1 Week
+4.54%
1 Month
-0.08%
3 Month
-1.33%
6 Month
+13.74%
1 Year
-4.63%
2 Year
-5.14%
5 Year
-20.17%
10 Year
-11.99%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 18.99 8.79 27.46 27.31 16.67 17.21 13.32 14.81 12.33
Return on Capital Employed (%) 15.04 12.40 18.53 20.54 14.77 16.47 14.04 15.30 14.19
Return on Assets (%) 7.51 2.58 8.52 11.33 7.40 7.98 6.17 7.11 6.74

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 2,983 1,783 3,630 4,493 5,163 5,605 6,071 7,065 9,087 9,573
Non Curr. Liab. 1,967 2,749 1,499 3,258 2,824 2,280 3,033 2,804 1,270 2,342
Curr. Liab. 2,949 3,777 3,999 2,703 3,288 4,021 4,126 4,201 4,689 4,198
Minority Int. 13 0 0 0 0 0 0 0 351 366
Equity & Liab. 7,912 8,309 9,128 10,453 11,275 11,906 13,229 14,069 15,397 16,479
Non Curr. Assets 3,150 2,978 3,224 3,578 4,286 5,209 6,425 6,709 7,115 7,520
Curr. Assets 4,763 5,331 5,904 6,875 6,989 6,697 6,804 7,360 8,282 8,959
Misc. Exp. not W/O
Total Assets 7,912 8,309 9,128 10,453 11,275 11,906 13,229 14,069 15,397 16,479

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 5,945 6,681 7,562 9,079 9,074 9,865 10,641 10,944 12,305 12,636
Other Income 11 7 20 37 91 208 160 50 167 464
Total Income 5,956 6,688 7,582 9,117 9,166 10,074 10,801 10,994 12,472 13,100
Total Expenditure -4,854 -5,467 -6,125 -7,043 -7,459 -8,280 -8,943 -8,860 -9,985 -10,499
PBIDT 1,102 1,221 1,457 2,074 1,707 1,794 1,858 2,135 2,487 2,601
Interest -189 -190 -179 -237 -286 -335 -377 -353 -298 -327
Depreciation -217 -300 -234 -264 -302 -326 -417 -444 -487 -596
Taxation -151 -334 -301 -383 -315 -376 -320 -412 -448 -676
Exceptional Items -187 -81 167 33 45 -261 -49
PAT 546 209 743 1,109 804 925 776 970 994 953
Minority Interest -3 0 0 0 0 0 0 -52 -72
Share Associate
Other Related Items
Consolidated Net Profit 542 210 743 1,109 804 925 776 970 942 881
Adjusted EPS 20 8 26 39 28 33 28 34 33 31

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 648 854 482 345 657 1,648 1,324 1,392 1,131 1,109
Cash Fr. Inv. -464 -368 -540 -880 -712 -1,013 -699 -784 -675 -333
Cash Fr. Finan. 195 -98 199 699 543 -469 -739 -445 -442 -520
Net Change 379 388 141 163 488 166 -114 164 14 255
Cash & Cash Eqvt 605 795 764 857 1,056 1,233 936 1,110 1,138 1,411

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 46.63 46.63 46.63 46.65 46.65 46.65 46.65 46.65 46.65
Public 53.37 53.37 53.37 53.35 53.35 53.35 53.35 53.35 53.35
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Mon, 20 Mar 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine Maleate Tablets USP 5 mg and 10 mg
Thu, 16 Mar 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby enclose copies of the newspaper advertisement informing about Postal Ballot Notice and e-Voting information published in Financial Express and Loksatta dated 15th March 2023. The same has been made available on the Companys website.
Thu, 16 Mar 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2 first-in-human clinical study of the molecule for the treatmentof patients with advanced solid tumors and lymphomas

Technical Scans View Details >>

Mon, 20 Mar 2023
Higher Delivery Quantity Higher Delivery Quantity
Close Crossing Last Week High Close Crossing Last Week High
Closing Above Previous High Closing Above Previous High
Closing Above Previous High For 3 Days Closing Above Previous High For 3 Days
Making Higher Highs for 3 days Making Higher Highs for 3 days

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 230,636.07 956.20 -0.5%
Divi's Laboratories Ltd. 74,303.33 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. 73,967.90 4,419.30 -0.5%
Cipla Ltd. 70,000.14 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. 61,905.77 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. 51,514.78 1,518.00 -0.3%
Zydus Lifesciences Ltd. 48,165.73 477.95 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 54.76 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-12 31.06 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.25 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-12 26.53 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 80.95 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 61.90 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-12 23.34 477.95 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.17 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-12 5.98 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.35 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-12 3.08 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.04 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.07 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.79 477.95 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 0.04 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 477.95 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 13.10 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 477.95 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 13.10 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 477.95 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 477.95 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 477.95 +0.4%

FAQ's On Glenmark Pharmaceuticals Ltd.

What is Glenmark Pharma share price?
Can I buy Glenmark Pharma shares now?
What is the Dividend Yield of Glenmark Pharma?
What is the Market Cap of Glenmark Pharma?
What are the key metrics to analyse Glenmark Pharma?
What is the 52 Week High and Low of Glenmark Pharma?
What is the trend of Glenmark Pharma share price?